MedDataX Logo

Improving Medication Therapy Through a Digital Interdisciplinary Medicine Therapy Optimisation Model

NCT ID: NCT05629936

Last Updated: 2024-12-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

8 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-11-22

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study investigates if a digital interdisciplinary medicine therapy optimisation (MTO) model in primary care can improve medication therapy, quality of life, medication adherence, and beliefs about medicines, among patients \>65 years living in sparsely populated areas. The intervention includes digital medication interviews, comprehensive medication reviews, interdisciplinary patient-centred discussions, and follow-ups.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Initially, a pilot study will be conducted to evaluate the feasibility of the method and to make appropriate adjustments to the study design before starting the main study. Patients that meet the inclusion criteria will be invited to participate in the study via letter. The patients will also receive three validated questionnaires; Medication Adherence Report Scale-5 (MARS-5), EuroQol-5 Dimension-5 Level questionnaire (EQ-5D-5L) and The Beliefs about Medicines Questionnaire (BMQ) to fill in prior to initiation of the study, to collect baseline data. The intervention consists of several steps and all meetings are digital. At first, the patient will have a medication interview with a clinical pharmacist, Next, the clinical pharmacist conducts a comprehensive medication review based on information from the interview and the participant's medical records and laboratory values. The clinical pharmacist and the participant's primary care physician will then have a joint discussion regarding preliminary medication management proposals and therapy management plans. The patient will be informed by their physician if any medication changes have been made. Digital follow-up meetings with the patient and the clinical pharmacist will take place 1-2, 4 and 12 weeks after the baseline consultation, and additionally if requested by the patient or if the pharmacist consider it necessary. The clinical pharmacist will also conduct repeated medical record reviews every second week during the 12-week intervention period. After the last follow-up at 12 weeks, the patient will be asked to fill in the three questionnaires: MARS-5, EQ-5D-5L and BMQ one more time.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Drug Use

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Telemedicine Medication reconciliation Clinical pharmacist Elderly Adherence Drug-related problems

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Digital intervention

Digital intervention

Group Type OTHER

Digital interdisciplinary intervention

Intervention Type OTHER

Digital medication interview, comprehensive medication review, interdisciplinary patient-centred discussions, follow-ups

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Digital interdisciplinary intervention

Digital medication interview, comprehensive medication review, interdisciplinary patient-centred discussions, follow-ups

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Using 5 or more medications or recommended by the primary care physician (e.g. according to the use of certain medicines or conditions such as chronic kidney disease)
* Living at home (i.e not in a nursing home)
* Registered at certain primary healthcare centres in the rural areas of Västerbotten

Exclusion Criteria

* Do not speak Swedish or unable to communicate
* Has home care services
* Has a confirmed major neurocognitive disorder
* Receives palliative care
Minimum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Region Västerbotten

OTHER_GOV

Sponsor Role collaborator

Umeå University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Maria Gustafsson

Principal investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Maria Gustafsson, Ph.D

Role: PRINCIPAL_INVESTIGATOR

Department of Medical and Translational Biology, Umeå University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Storuman healthcare centre

Storuman, , Sweden

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Sweden

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

UMU-MTO-2022

Identifier Type: -

Identifier Source: org_study_id